Grifols A : H1 2022 results confirm the pathway towards plasma normalisation but high debt levels remain
>Better-than-expected H1 2022 sales at Bioscience (7% above) - The company now reports on a half-yearly basis: H1 2022 group sales increased +11% y-o-y to € 2.8bn (vs -10% in H2 2021 and the company’s indication of mid-to-high single digit in Q1 2022). This growth reported is also above the company’s guidance of c.+5% for the period provided at its CMD last June. Organic growth excluding forex was +3% (vs -10% in H2 2021, low-single-digit at cc in Q1 2022 and company’...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.